Special Issue "Novel Therapeutic Targets and Drug Candidates for the Treatment of Eye Diseases"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 7691
Vision is an essential part of life. Loss of vision can directly compromise a person’s quality of life and indirectly impact their health. People with vision loss are more likely to report depression, falls, cognitive decline, and premature death. With an increased aging population, vision impairment has become a major global public health problem. Recent breakthroughs, including the use of the artificial intraocular lens for cataracts and anti-VEGF molecules for wet age-related macular degeneration (AMD) are some impressive examples of restoring vision. However, many unmet needs remain in the field of ocular diseases, particularly for glaucoma, diabetic retinopathy, and AMD. Moreover, due to the presence of blood–ocular barriers, ocular drug delivery has always been a challenge for ophthalmologists and pharmaceutical scientists.
In this Special Issue, we invite both reviews and original research articles related to ophthalmic drug discovery. The major goal is to highlight some of the recent findings in the field, and to discuss new drug delivery technologies and possible future targets. Topics of the Special Issue include, but are not limited to, emerging drug targets; novel drug delivery systems; new drug candidates; and old drug repurposing for eye diseases. The collection of manuscripts will be published as a Special Issue of the journal.
Dr. Hongli Wu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- retinal degeneration
- diabetic retinopathy
- drug target
- drug delivery
- drug candidate
- gene therapy
- stem cells
- natural products